Aliskiren drug interactions | Litt's Drug Eruption and Reaction Database

Aliskiren comment watch save

TRADE NAMES: Rasilez (Novartis); Tekamlo (Novartis); Tekturna (Novartis); Tekturna HCT (Novartis); Valturna (Novartis)
INDICATIONS: Hypertension
CLASS: Antihypertensive, Renin inhibitor
HALF-LIFE: 24 hours

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
ACE inhibitors, Aldosterone antagonists, Atorvastatin, Candesartan, Celecoxib, Cyclosporine, Diclofenac, Furosemide, Heparin, Irbesartan, Itraconazole, Ketoconazole, Losartan, Meloxicam, Moexipril, NSAIDs, Olmesartan, Potassium salts, Potassium-sparing diuretics, Sacubitril/Valsartan, Tinzaparin, Trandolapril, Verapamil
PREGNANCY: category C in first trimester; category D in second and third trimesters

See adverse reactions attributed to class:
Antihypertensive

Tekamlo is aliskiren and amlodipine; Tekturna HCT is aliskiren and hydrochlorothiazide; Valturna is aliskiren and valsartan.

Hydrochlorothiazide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.

Contra-indicated for concomitant use with angiotensin receptor blockers or angiotensin-converting enzyme (ACE) inhibitors in patients with diabetes.

FETAL TOXICITY

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

DRUG REVIEW ARTICLE

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of aliskiren in the Taylor & Francis journal Expert Opinion on Drug Safety.

(Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 07/31/2023

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

Breast feeding

Geriatric

Pediatric